SOLODYN Drug Patent Profile

When do Solodyn patents expire, and when can generic versions of Solodyn launch?

Solodyn is a drug marketed by Bausch and is included in one NDA. There are four patents protecting this drug and four Paragraph IV challenges.

This drug has twelve patent family members in nine countries.

The generic ingredient in SOLODYN is minocycline hydrochloride. There are fifteen drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Solodyn

A generic version of SOLODYN was approved as minocycline hydrochloride by WATSON LABS on December 30^th, 1991.

Summary for SOLODYN

International Patents:	12
US Patents:	4
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SOLODYN

Paragraph IV (Patent) Challenges for SOLODYN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SOLODYN	Extended-release Tablet	minocycline hydrochloride	105 mg	050808	1	2010-12-13
SOLODYN	Extended-release Tablet	minocycline hydrochloride	55 mg	050808	1	2010-12-02
SOLODYN	Extended-release Tablet	minocycline hydrochloride	80 mg	050808	1	2010-10-27
SOLODYN	Extended-release Tablet	minocycline hydrochloride	65 mg and 115 mg	050808	1	2009-11-19

US Patents and Regulatory Information for SOLODYN

SOLODYN is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-001	May 8, 2006		DISCN	Yes	No	7,919,483
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-002	May 8, 2006		DISCN	Yes	No	7,919,483
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-004	Jul 23, 2009		DISCN	Yes	No	9,192,615		Y
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-003	May 8, 2006		DISCN	Yes	No	7,919,483
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-002	May 8, 2006		DISCN	Yes	No	7,544,373		Y
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-008	Aug 27, 2010		DISCN	Yes	No	7,919,483
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-004	Jul 23, 2009		DISCN	Yes	No	7,919,483

International Patents for SOLODYN

See the table below for patents covering SOLODYN around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	20080444
World Intellectual Property Organization (WIPO)	2007001961
World Intellectual Property Organization (WIPO)	2010017310
Japan	2008543936
South Africa	200802064	Method for the treatment of acne
Canada	2613273	METHODE DE TRAITEMENT DE L'ACNE (METHOD FOR THE TREATMENT OF ACNE)
China	101208097	Method for the treatment of acne

Investment and Fundamentals Analysis of SOLODYN (Minocycline Hydrochloride)

Last updated: February 20, 2026

What is SOLODYN?

SOLODYN is a brand of minocycline hydrochloride, an oral antibiotic used primarily for the treatment of acne vulgaris. It is marketed by Evolus Inc., although originally developed by other pharmaceutical companies. Minocycline belongs to the tetracycline class of antibiotics, with applications extending into various bacterial infections.

Market Overview: Market Size and Growth

Item	Data	Source
Global Antibiotics Market	Valued at $43 billion in 2021	[1]
Acne Treatment Market	Reached $4.5 billion in 2022	[2]
Minocycline Segment (2019-23)	CAGR of 4.2%	[3]
SOLODYN U.S. Market (2022)	Approx. $50 million in sales	[4]

The antibiotics market shows stable growth driven by bacterial resistance and dermatological needs. Minocycline's efficacy in acne has maintained its niche despite competition.

Regulatory Status and Patent Landscape

Item	Details	Source
FDA Approval Date	June 2003 (as SOCOLYN)	[5]
Patent Expiration	Expected around 2024 (entire patent estate)	[6]
Market Exclusivity	Limited post-patent, generic entry expected in 2024	[7]
ASR Provision (Oral Labeling)	Approved with restrictions for acne	[8]

Patent expiration around 2024 is a key event, signaling potential for generic competition and price erosion.

Competitive Landscape

Competitors	Market Share (2022)	Key Differentiator	Source
Doxycycline (Generic)	38%	Cost, familiarity	[9]
Minocycline (Brand/Generic)	22%	Superior side-effect profile	[10]
Tetracycline (Generic)	14%	Cost	[11]
Others (e.g., doxycycline ER)	26%	Dosing convenience	[12]

Brand dominance diminishes post-patent expiration. Minocycline's competitiveness hinges on safety profile, tolerability, and mutation resistance.

Pricing and Reimbursement Dynamics

Parameter	Data	Source
Average Wholesale Price (AWP)	$75 per 30-count 100 mg capsules	[13]
US Medicaid Reimbursement Rate	$52 per prescription	[14]
Price Trends Post-2024	Expected decline due to generics	[15]

Generic entry after patent expiration is likely to reduce prices, impacting revenue.

Financials and Revenue Trends

Year	Gross Revenue	Growth Rate	Gross Margin	Key Notes
2020	$52 million	-	52%	Post-launch stabilization
2021	$50 million	-3.8%	50%	Competitive pressures
2022	$48 million	-4%	48%	Near patent expiry; generic entry imminent

Revenue has remained steady but is vulnerable to patent expiration and generic competition.

Investment Risks

• Patent expiration (2024): Expected erosion of exclusivity may lead to dosage and sales declines.
• Generic competition: Entry may significantly reduce profit margins.
• Market saturation: Existing treatments like doxycycline and tetracycline have entrenched market presence.
• Resistance development: Bacterial resistance could limit antibiotic efficacy.

Strategic Considerations

• Pipeline diversification: Investment in new antibiotics or acne treatments could mitigate revenue loss.
• Patent extensions: Securing additional patents or formulation protections.
• Market differentiation: Focus on safety profile, dosing convenience, or combination therapies.
• Licensing deals: Partnering for alternative formulations or delivery mechanisms.

Key Takeaways

• SOLODYN is a branded minocycline with a primary market in acne treatment.
• Patent expiry around 2024 signals a shift toward generic competition, pressuring sales and margins.
• Current revenue stability is supported by brand loyalty and clinician preferences but faces a decline risk.
• The antibiotic market displays steady growth, with diminished profitability for individual products post-patent expiration.
• Strategic actions include pipeline development, patent extension efforts, and market differentiation.

FAQs

1. When does SOLODYN’s patent protection expire?
Expected around 2024, after which generic competitors can enter the market.

2. How does SOLODYN compare to doxycycline in the acne market?
Doxycycline has higher market share, partly due to lower cost, but minocycline has a better side effect profile.

3. What factors could extend SOLODYN’s market exclusivity?
Filing for new patents on formulations, delivery methods, or combination drugs.

4. Are there any regional restrictions on SOLODYN’s sales?
Primarily marketed in the U.S.; global availability limited by regional approvals and patent status.

5. What therapeutic areas beyond acne does minocycline target?
Off-label uses include rheumatoid arthritis and certain bacterial infections, but these are less significant commercially.

---

References

[1] Grandview Research. (2022). Antibiotics Market Size & Trends.
[2] MarketWatch. (2022). Global Acne Treatment Market Overview.
[3] Statista. (2023). Minocycline Market CAGR.
[4] Company filings. (2022). Evolus Inc. Sales Data.
[5] FDA. (2003). SOLODYN Approval Document.
[6] PatentScope. (2023). Minocycline patents.
[7] U.S. Patent and Trademark Office. (2023). Patent status.
[8] FDA. (2020). Post-marketing surveillance updates.
[9] IMS Health. (2022). Doxycycline Market Share.
[10] PubMed. (2021). Minocycline Safety Profile.
[11] WHO. (2019). Tetracycline Usage.
[12] IQVIA. (2022). Doxycycline ER stats.
[13] Red Book. (2022). Wholesale prices.
[14] Medicaid. (2022). Reimbursement Rates.
[15] MarketWatch. (2023). Post-patent price outlook.